Ecolab (ECL)
(Delayed Data from NYSE)
$247.23 USD
+1.00 (0.41%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $247.10 -0.13 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$247.23 USD
+1.00 (0.41%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $247.10 -0.13 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Zacks News
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.
KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan
by Zacks Equity Research
KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan.
Merit Medical (MMSI) Inks Deal to Boost Endoscopy Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) latest asset acquisition is likely to expand its endoscopy portfolio with a minimally-invasive solution for GERD patients, thereby improving patient outcomes.
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
by Zacks Equity Research
IceCure Medical's (ICCM) XSense Cryoablation System receives FDA approval, marking a pivotal step in minimally-invasive tumor treatment across multiple medical fields
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Freeport (FCX) Starts Commissioning of New Indonesian Smelter
by Zacks Equity Research
Freeport (FCX) anticipates that the smelter will begin producing copper cathodes in the following months and that it will reach full ramp-up by the end of 2024.
DuPont (DD) to Feature Kalrez Solutions at SEMICON West 2024
by Zacks Equity Research
DuPont's (DD) Kalrez perfluoroelastomer parts portfolio comprises O-rings, custom-designed components and bonded parts that incorporate metals, glass, ceramics and fibers.
Avantor (AVTR) Launches Solutions for Gene Therapy Harvest
by Zacks Equity Research
Avantor's (AVTR) solutions are intended to provide gene therapy manufacturers with sustainable and efficient alternatives to traditional methods, thus improving viral particle harvest and quality
Masimo's (MASI) WI Sport Wearable Gets a New Powerful Feature
by Zacks Equity Research
Masimo (MASI) announces Sleep Halo, a new feature for its Masimo W1 Sport advanced health tracking wearable.
GE Healthcare (GEHC) Enters Partnership to Boost MRI Technology
by Zacks Equity Research
GE Healthcare's (GEHC) alliance is likely to establish an Innovative MRI Research and Development center to advance MRI innovation and patient care
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
Nexa Resources (NEXA) Sells Morro Agudo Complex to Casa Verde
by Zacks Equity Research
Nexa Resources (NEXA) sells its Morro Agudo Complex to optimize its portfolio.
B2Gold (BTG) Inks Deal to Buy 9.99% Stake in Prospector Metals
by Zacks Equity Research
B2Gold (BTG) to buy 5.6 million shares of Prospector Metals and become part of its technical committee.
Air Liquide's (AIQUY) Transformation Plan to Drive Efficiency
by Zacks Equity Research
Air Liquide's (AIQUY) strong business model and successful implementation of its ADVANCE strategic plan have put the company in on a solid footing.
PacBio (PACB) and Form Bio to Boost AAV Industry Development
by Zacks Equity Research
PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.
H.B. Fuller (FUL) Q2 Earnings and Sales Beats Estimates
by Zacks Equity Research
H.B. Fuller's (FUL) second-quarter earnings and sales top estimates on higher gross margins and volumes.
Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.
CalMaine Foods (CALM) Acquires ISE America Assets for $110M
by Zacks Equity Research
CalMaine Foods (CALM) buys assets of ISE to boost market reach in the Northeast and Mid-Atlantic states.
DOW & Fiori Team Up to Advance Sustainable Vehicle Recycling
by Zacks Equity Research
The Fiori Group and DOW MobilityScience teams will collaborate openly to produce a valuable prototype for recycling EOL vehicle parts and materials.
Here's Why You Should Buy Axalta Coating (AXTA) Stock Now
by Zacks Equity Research
Axalta Coating (AXTA) looks promising based on its robust Q1 results and the acquisition of The CoverFlexx Group.
Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care
by Zacks Equity Research
Masimo (MASI) collaborates with Cleveland Clinic to boost patient care by combining its Hospital Automation platform with the latter's central patient monitoring platforms.
Westlake's (WLK) Subsidiary Invests in Blackhorn Ventures
by Zacks Equity Research
Westlake's (WLK) action builds on the company's commitment to contributing to a more sustainable future through continual development of its own manufacturing as well as strategic investments.
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
by Zacks Equity Research
BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.